Biotechnology company developing small-molecule therapeutics for previously undruggable disease targets
Biotechnology company developing small-molecule therapeutics for previously undruggable disease targets. Its proprietary IMTAC chemoproteomics platform screens compounds across proteins in live cells, combining covalent chemistry and proteome-wide insights to identify drug candidates. The company has a therapeutic pipeline and collaborates with pharmaceutical partners on oncology, immunology, neurology, and neurodegenerative disease programs.